Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc. (GRCL) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
grcl · stock forecast · 8 analysts (3M) · FMP · updated Mar 26, 2024
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Hold
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$6.00
Consensus
$6.00
-41.5% upside
Low
$6.00
Median: $6 · Last Close: $10.25
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $10.25 | ↓ 0.05% |
1-day model range: $10.24–$10.26. Peak: $10.26 (-0.05%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · GRCL · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-02-22 | Stifel | Downgrade ↓ | Buy→Hold |
| 2023-12-27 | Wells Fargo | Downgrade ↓ | Overweight→Equal Weight |
| 2023-12-27 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2023-12-26 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2023-12-26 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2023-09-05 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-09-04 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-08-30 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-08-29 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-08-29 | Citigroup | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Gracell Biotechnologies Inc. (GRCL) stock. Of the recent 27 rating actions, 0 were upgrades and 5 were downgrades. 8 analysts currently cover GRCL.
Analyst Recommendation Trends
GRCL analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
Revenue Next Year
$0M
↓ 65.8% YoY
EPS This Year
$-0.10
EPS Next Year
$-0.68
↑ 580.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast GRCL EPS of $-0.10 for the current fiscal year, based on estimates from 0 analysts. The GRCL revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The GRCL stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GRCL price target is $6.00 (-41.5% upside), with an analyst consensus of Hold.
The GRCL short-term stock prediction for tomorrow is $10.25 (-0.05%).
Gracell Biotechnologies Inc. trades on NASDAQ under the ticker GRCL. The GRCL stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 38% of covering analysts.
Frequently asked questions
GRCL forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month GRCL price target is $6.00, with a high forecast of $6.00 and a low of $6.00. The median price target is shown in the chart above when available. This implies -41.5% potential upside from the current price of $10.25.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.